Measures in Rheumatoid Arthritis

Fig. 1

Radiographic outcomes in randomized controlled trials with methotrexate-naïve patients. TNF tumor necrosis factor inhibitor, MTX methotrexate, ETA etanercept, IFX infliximab, ADA adalimumab, ERA early rheumatoid arthritis (From Yazici and Yazici [44])

Conclusions

Use of standardized outcome measures in rheumatology increased significantly over the last decade and led to improvements in comparability of clinical studies across different settings and patient care. RA is the condition that drove the development of standardized outcome measures in rheumatology followed by other rheumatologic conditions. Many of the currently used standardized outcome measures in RA (i.e., DAS28, CDAI, SDAI, RAPID3, HAQ) are based on the Core Data Set that includes patient-reported (physical function, pain, patient global estimate of status), physical examination (swollen joint count, tender joint count, physician/assessor patient global estimate of status), and laboratory (ESR or CRP) measures. With increased understanding of the underlying disease processes in RA, there is growing interest in the development of imaging and biomarker-based measures that can be used in conjunction with patient-reported and physical examination measures to improve measurement of disease activity in RA.

References

Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol. 2008;26:814–9.PubMed

Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36:729–40.PubMedCrossRef

Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9.PubMedCrossRef

Verstappen SM, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443–9.PubMedCentralPubMedCrossRef

Goekoop-Ruiterman YP, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381–90.PubMedCrossRef

Pincus T. The American College of Rheumatology (ACR) Core Data Set and derivative “patient only” indices to assess rheumatoid arthritis. Clin Exp Rheumatol. 2005;23 Suppl 39:S109–13.PubMed

Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–35.PubMedCrossRef

Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O’Dell JR, Kazi S. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640–7. doi:10.1002/acr.21649.CrossRef

van der Heijde DMFM, van’t Hof M, van Riel PLCM, van de Putte LBA. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20:579–81.PubMed

10.

Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.PubMedCrossRef

11.

Fransen J, Stucki G, van Riel PL. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum. 2003;49 Suppl 9:S214–24.CrossRef

12.

Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) global assessment of disease activity, Disease Activity Score (DAS) and Disease Activity Score with 28-joint counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), patient-based Disease Activity Score with ESR (PDAS1) and patient-based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011;63(Suppl):S14–36.CrossRef

13.

Prevoo ML, van Gestel AM, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996;35:1101–5.PubMedCrossRef

Only gold members can continue reading. Log In or Register to continue